TEPLI-REALTeplizumab Use in Type 1 Diabetes Patients

This study focuses on Type 1 Diabetes Mellitus (T1D), a chronic condition where the immune system attacks the pancreas' beta cells, leading to insulin deficiency. T1D progresses in three stages, from the presence of autoantibodies without symptoms, to dysglycemia, and finally to overt hyperglycemia and symptoms, typically requiring insulin treatment. Teplizumab, a drug approved in the USA, has shown to delay progression to the final stage in patients at stage 2. This observational study aims to gather data on the use of Teplizumab in routine care, helping to understand which patients receive the drug and how they are managed post-treatment, especially for patients outside the USA who receive it through special programs. Participants in this study will have their blood glucose levels monitored using Continuous Glucose Monitoring (CGM) systems. The study will also record participant demographics at the start of Teplizumab treatment, including age, sex at birth, height, weight, and Body Mass Index (BMI). Additionally, it will document the participants' family history of T1D and other autoimmune diseases, their medical history related to T1D, and the presence of T1D susceptibility genes. The study will evaluate these factors to better understand the effects and outcomes of Teplizumab treatment in real-world scenarios.